Volume 8, Issue 2 (5-2022)                   RABMS 2022, 8(2): 75-82 | Back to browse issues page

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Samimagham H R, Hassani Azad M, Arabi M, Hooshyar D, Abbasi M A, Haddad M et al . The Efficacy of Famotidine in Improvement of Outcomes in Hospitalized COVID-19 Patients: A Phase III Randomized Clinical Trial. RABMS. 2022; 8 (2) :75-82
URL: http://ijrabms.umsu.ac.ir/article-1-183-en.html
Endocrinology and Metablism Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran , mitra.kazemijahromi@gmail.com
Abstract:   (100 Views)
Background & Aims:  As the first randomized clinical trial, this study evaluated the effect of Famotidine on the improvement of outcomes of hospitalized patients with COVID-19.
Materials & Methods: This phase III randomized clinical trial which was designed with two parallel arms, is a placebo-controlled, single-blind, and concealed allocation study, and recruited 20 patients (10 of them received Famotidine as treatment group and 10 received Placebo as control group). Oral Famotidine 160 mg four times a day was given to the COVID-19 patients until the discharge day or for a maximum of 14 days. Patients’ temperature, respiration rate, oxygen saturation, lung infiltration, lactate dehydrogenase (LDH) level, and complete blood count (CBC) were measured at the baseline (before the intervention) and on day 14 after the intervention or on discharge day. Length of stay in the hospital and length of stay in the ICU were also measured as secondary outcomes of the study.
Results: The results showed a significant decrease in LDH (P=0.01), mean WBC (P=0.04) and length of stay (P=0.04) of patients with COVID-19 in the group treated with Famotidine compared to the control group. There was also a significant increase in oxygen saturation (P=0.01) in the group treated with Famotidine compared to the control group. Cough improvement was also higher in the oral Famotidine group compared to the control group (P=0.02).
Conclusion: This was the first clinical trial on the effect of Famotidine on the improvement of hospitalized COVID-19 patients, which indicated that high-dose Famotidine improves patients’ clinical signs and reduces the severity of the disease and duration of hospitalization.
Full-Text [PDF 497 kb]   (42 Downloads)    
Type of Study: orginal article | Subject: Special

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2022 CC BY-NC 4.0 | Journal of Research in Applied and Basic Medical Sciences

Designed & Developed by : Yektaweb